Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity.

ABSTRACT:

Objective

To test the hypothesis that accelerated peripheral blood mononuclear cell recovery after alemtuzumab treatment of multiple sclerosis is associated with recurrent disease activity and to investigate the claim that CD4 counts greater than 388.5 × 10(6) cells/mL at 12 months can be used to identify patients who may benefit from further treatment.

Methods

A total of 108 patients were followed for a median of 99 months post alemtuzumab. Patients were classified as active or nonactive after each cycle of treatment based on clinical relapse, increasing disability, or new T2/enhancing MRI lesions. These outcomes were correlated with CD4, CD8, CD19, CD56+ NK, and monocyte counts.

Results

Of 108 patients, 56 (52%) relapsed at some point during follow-up. Mean annualiz

SUBMITTER: Kousin-Ezewu O 

PROVIDER: S-EPMC4113466 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature